A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension

Phase 3 Completed 37 enrolled AbbVie

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study will evaluate the 24-hour intraocular pressure lowering effect and safety after a single administration of Bimatoprost SR in patients with Open-Angle Glaucoma or Ocular Hypertension

Timeline

Start: 2020-06-11
Primary completion: 2022-05-14
Completion: 2022-05-14

Publications

Weinreb RN, Christie WC, Medeiros FA, Craven ER, Kim K, Nguyen A, Bejanian M, Wirta DL. Single Administration of Bimatoprost Implant: Effects on 24-Hour Intraocular Pressure and 1-Year Outcomes. Ophthalmol Glaucoma. 2023 Nov-Dec;6(6):599-608. doi: 10.1016/j.ogla.2023.06.007. Epub 2023 Jun 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bimatoprost	Other / unclassified	10 ug	Intravitreal
Subject	Bimatoprost	Other / unclassified	0.01 %	Topical

A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension

Summary

Timeline

Publications

Drugs

Indications